A Phase 3 interventional study of 20-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine in Pneumococcal Disease, sponsored by Pfizer. Completed at 38 sites in Japan. Open to participants aged 2 Months to 6 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-21.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 10th largest by enrollment, is one of 5 that started in 2020, is one of 14 in phase 3, and was the 7th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 42 days–98 days · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United States
Ages 2 mo–15 mo · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 2 Months to 6 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 5 started in 2020.
This study's enrollment of 668 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 668 across the 19 interventional studies. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 4 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 27th largest by enrollment of the 57 interventional ones that give a count, is one of 6 that started in 2020, is one of 33 in phase 3, and was the 53rd registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
1 of the studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07023081PfizerA Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | 2027-06-10 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)
Biological: 20-valent pneumococcal conjugate vaccine
13-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)
Biological: 13-valent pneumococcal conjugate vaccine
20-valent pneumococcal conjugate vaccine administered by intramuscular injection (IM)
Biological: 20-valent pneumococcal conjugate vaccine
20-valent pneumococcal conjugate vaccine
13-valent pneumococcal conjugate vaccine
Percentage of Participants With Local Reactions (LR) Within 7 Days After Dose 1
Local reactions included pain at injection site, redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 centimeter (cm). Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: \>0 to 2.0 cm; moderate \>2.0 to 7.0 cm; and severe: \>7.0 cm.
Time frame: Within 7 Days after Dose 1
Percentage of Participants With Local Reactions Within 7 Days After Dose 2
Local reactions included pain at injection site, redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: \>0 to 2.0 cm; moderate \>2.0 to 7.0 cm; and severe: \>7.0 cm.
Time frame: Within 7 Days after Dose 2
Percentage of Participants With Local Reactions Within 7 Days After Dose 3
Local reactions included pain at injection site, redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: \>0 to 2.0 cm; moderate \>2.0 to 7.0 cm; and severe: \>7.0 cm.
Time frame: Within 7 Days after Dose 3
Percentage of Participants With Local Reactions Within 7 Days After Dose 4
Local reactions included pain at injection site, redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: \>0 to 2.0 cm; moderate \>2.0 to 7.0 cm; and severe: \>7.0 cm.
Time frame: Within 7 Days after Dose 4
Percentage of Participants With Systemic Events Within 7 Days After Dose 1
Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature greater than or equal to (\>=) 37.5 degree Celsius (C), and categorized as \>=37.5 to 38.4 degree C, greater than (\>)38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).
Time frame: Within 7 Days After Dose 1
Percentage of Participants With Systemic Events Within 7 Days After Dose 2
Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature \>=37.5 degree C and categorized as \>=37.5 to 38.4 degree C,\>38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).
Time frame: Within 7 Days After Dose 2
Percentage of Participants With Systemic Events Within 7 Days After Dose 3
Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature \>=37.5 degree C and categorized as \>=37.5 to 38.4 degree C,\>38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).
Time frame: Within 7 Days After Dose 3
Percentage of Participants With Systemic Events Within 7 Days After Dose 4
Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature \>=37.5 degree C and categorized as \>=37.5 to 38.4 degree C,\>38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).
Time frame: Within 7 Days After Dose 4
Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3
An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Time frame: Day 1 of Dose 1 to 1 Month after Dose 3
Percentage of Participants With AEs From Dose 4 to 1 Month After Dose 4
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Time frame: From Dose 4 to 1 Month after Dose 4
Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 4
A serious AE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; congenital anomaly/birth defect and other important medical events.
Time frame: From Dose 1 to 1 Month after Dose 4
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 1 Month After Dose 4
An NDCMC was defined as a significant disease or medical condition, not previously identified, that is expected to be persistent or was otherwise long-lasting in its effects.
Time frame: From Dose 1 to 1 Month after Dose 4
Percentage of Participants With Predefined Pneumococcal Serotype-specific Immunoglobulin G (IgG) Concentrations 1 Month After Dose 3
Pneumococcal serotype-specific IgG Concentrations were measured for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. The predefined levels, \>=0.35 micrograms/mL for all serotypes except for serotypes 5 (\>=0.23 micrograms/mL), 6B (\>=0.10 micrograms/mL) and 19A (\>=0.12 micrograms/mL).
Time frame: 1 Month after Dose 3
Geometric Mean Concentration of Pneumococcal Serotype-Specific IgG Concentrations 1 Month After Dose 3
Pneumococcal serotype-specific IgG concentrations were measured for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: 1 Month after Dose 3
Geometric Mean Concentration of Pneumococcal Serotype-Specific IgG Concentrations 1 Month After Dose 4
Pneumococcal serotype-specific IgG concentrations were measured for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F.
Time frame: 1 Month after Dose 4
Geometric Mean Titer (GMTs) of Serotype Specific Opsonophagocytic Activity (OPA) at 1 Month After Dose 3, Before Dose 4 and 1 Month After Dose 4
20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. OPA titers were determined in randomly selected subsets of sera from each vaccine group.
Time frame: 1 Month after Dose 3, before Dose 4 and 1 Month after Dose 4
Percentage of Participants With Pre-defined Pneumococcal Serotype-specific IgG Concentrations at 1 Month After Dose 4
Pneumococcal serotype-specific IgG concentrations were measured for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. The predefined levels, \>=0.35 micrograms/mL for all serotypes except for serotypes 5 (\>=0.23 micrograms/mL), 6B (\>=0.10 micrograms/mL) and 19A (\>=0.12 micrograms/mL).
Time frame: 1 Month after Dose 4
Geometric Mean Fold Rise (GMFR) in Serotype-Specific IgG Concentrations From 1 Month After Dose 3 to Before Dose 4
GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. The GMFR from 1 month after Dose 3 to before Dose 4 was reported from participants in Dose 3 evaluable immunogenicity population.
Time frame: 1 Month after Dose 3 to before Dose 4
GMFR in Serotype-Specific IgG Concentrations From 1 Month After Dose 3 to 1 Month After Dose 4
GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. The GMFR from 1 month after Dose 3 to 1 month after Dose 4 was reported from participants in both the Dose 3 and Dose 4 evaluable immunogenicity population.
Time frame: From 1 Month after Dose 3 to 1 Month after Dose 4
GMFR in Serotype-Specific IgG Concentrations From Before Dose 4 to 1 Month After Dose 4
GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. The GMFR from before Dose 4 to 1 month after Dose 4 was reported from participants in the Dose 4 evaluable immunogenicity population.
Time frame: From before Dose 4 to 1 Month after Dose 4
| Milestone | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Started | 225 | 224 | 217 |
| Completed | 217 | 220 | 211 |
| Not completed | 8 | 4 | 6 |
| Withdrew: Other | 2 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: No longer meets eligibility criteria | 1 | 0 | 2 |
| Withdrew: Withdrawal by parent/guardian | 5 | 2 | 2 |
Local reactions included pain at injection site, redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 centimeter (cm). Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: \>0 to 2.0 cm; moderate \>2.0 to 7.0 cm; and severe: \>7.0 cm.
| Percentage of participants | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Redness: Mild | 58.2 ± 51.5 | 51.3 ± 44.6 | 26.3 ± 20.5 |
| Redness: Moderate | 20.0 ± 15.0 | 23.7 ± 18.3 | 11.1 ± 7.2 |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Mild | 48.9 ± 42.2 | 42.9 ± 36.3 | 17.5 ± 12.7 |
| Swelling: Moderate | 19.6 ± 14.6 | 23.2 ± 17.9 | 11.1 ± 7.2 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at the injection site: Mild | 15.6 ± 11.1 | 13.4 ± 9.2 | 12.4 ± 8.4 |
| Pain at the injection site: Moderate | 1.8 ± 0.5 | 2.7 ± 1.0 | 3.2 ± 1.3 |
| Pain at the injection site: Severe | 0 ± 0.0 | 0 ± 0.0 | 0.5 ± 0.0 |
Local reactions included pain at injection site, redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: \>0 to 2.0 cm; moderate \>2.0 to 7.0 cm; and severe: \>7.0 cm.
| Percentage of participants | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Redness: Mild | 52.9 ± 46.1 | 53.2 ± 46.4 | 24.7 ± 19.0 |
| Redness: Moderate | 23.3 ± 17.9 | 31.1 ± 25.1 | 7.0 ± 4.0 |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Mild | 46.2 ± 39.5 | 46.8 ± 40.1 | 18.1 ± 13.2 |
| Swelling: Moderate | 22.4 ± 17.1 | 26.6 ± 20.9 | 7.9 ± 4.7 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at the injection site: Mild | 13.0 ± 8.9 | 16.7 ± 12.0 | 9.3 ± 5.8 |
| Pain at the injection site: Moderate | 3.6 ± 1.6 | 0.5 ± 0.0 | 2.3 ± 0.8 |
| Pain at the injection site: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Local reactions included pain at injection site, redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: \>0 to 2.0 cm; moderate \>2.0 to 7.0 cm; and severe: \>7.0 cm.
| Percentage of participants | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Redness: Mild | 45.0 (38.4 to 51.8) | 51.1 (44.3 to 57.9) | 23.3 (17.8 to 29.5) |
| Redness: Moderate | 33.8 (27.6 to 40.4) | 34.8 (28.6 to 41.5) | 8.4 (5.0 to 12.9) |
| Redness: Severe | 0 (0.0 to 1.6) | 0 (0.0 to 1.7) | 0 (0.0 to 1.7) |
| Swelling: Mild | 38.7 (32.3 to 45.5) | 39.8 (33.3 to 46.6) | 17.7 (12.8 to 23.4) |
| Swelling: Moderate | 30.2 (24.2 to 36.7) | 35.3 (29.0 to 42.0) | 9.8 (6.1 to 14.5) |
| Swelling: Severe | 0 (0.0 to 1.6) | 0 (0.0 to 1.7) | 0 (0.0 to 1.7) |
| Pain at the injection site: Mild | 10.8 (7.1 to 15.7) | 14.5 (10.1 to 19.8) | 8.8 (5.4 to 13.5) |
| Pain at the injection site: Moderate | 3.6 (1.6 to 7.0) | 1.4 (0.3 to 3.9) | 0.9 (0.1 to 3.3) |
| Pain at the injection site: Severe | 0 (0.0 to 1.6) | 0 (0.0 to 1.7) | 0.5 (0.0 to 2.6) |
Local reactions included pain at injection site, redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: \>0 to 2.0 cm; moderate \>2.0 to 7.0 cm; and severe: \>7.0 cm.
| Percentage of participants | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Redness: Mild | 37.2 (30.7 to 43.9) | 36.4 (30.0 to 43.1) | 20.8 (15.5 to 26.8) |
| Redness: Moderate | 49.1 (42.3 to 55.9) | 49.1 (42.3 to 55.9) | 11.8 (7.8 to 16.9) |
| Redness: Severe | 0.5 (0.0 to 2.5) | 0.5 (0.0 to 2.5) | 0 (0.0 to 1.7) |
| Swelling: Mild | 37.6 (31.2 to 44.4) | 35.9 (29.6 to 42.6) | 13.2 (9.0 to 18.5) |
| Swelling: Moderate | 42.2 (35.6 to 49.1) | 41.8 (35.2 to 48.6) | 10.8 (7.0 to 15.8) |
| Swelling: Severe | 0.5 (0.0 to 2.5) | 0 (0.0 to 1.7) | 0 (0.0 to 1.7) |
| Pain at the injection site: Mild | 19.7 (14.7 to 25.6) | 19.1 (14.1 to 24.9) | 10.4 (6.6 to 15.3) |
| Pain at the injection site: Moderate | 1.4 (0.3 to 4.0) | 3.2 (1.3 to 6.4) | 3.3 (1.3 to 6.7) |
| Pain at the injection site: Severe | 0 (0.0 to 1.7) | 0 (0.0 to 1.7) | 0 (0.0 to 1.7) |
Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature greater than or equal to (\>=) 37.5 degree Celsius (C), and categorized as \>=37.5 to 38.4 degree C, greater than (\>)38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).
| Percentage of participants | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Fever: >=37.5 degree C | 9.8 ± 6.2 | 12.9 ± 8.8 | 9.7 ± 6.1 |
| Fever: >=37.5°C to 38.4 degree C | 9.3 ± 5.9 | 12.5 ± 8.5 | 9.7 ± 6.1 |
| Fever: >38.4°C to 38.9 degree C | 0.4 ± 0.0 | 0.4 ± 0.0 | 0 ± 0.0 |
| Fever: >38.9 to 40.0 degree C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >40.0 degree C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Decreased appetite: Mild | 3.6 ± 1.5 | 7.1 ± 4.1 | 3.2 ± 1.3 |
| Decreased appetite: Moderate | 1.8 ± 0.5 | 3.1 ± 1.3 | 3.2 ± 1.3 |
| Decreased appetite: Severe | 0 ± 0.0 | 0.4 ± 0.0 | 0 ± 0.0 |
| Drowsiness: Mild | 40.4 ± 34.0 | 42.0 ± 35.4 | 42.9 ± 36.2 |
| Drowsiness: Moderate | 0.9 ± 0.1 | 2.2 ± 0.7 | 4.1 ± 1.9 |
| Drowsiness: Severe | 0 ± 0.0 | 0.4 ± 0.0 | 0 ± 0.0 |
| Irritability: Mild | 13.8 ± 9.6 | 11.2 ± 7.4 | 12.9 ± 8.7 |
| Irritability: Moderate | 12.0 ± 8.1 | 13.4 ± 9.2 | 11.5 ± 7.6 |
| Irritability: Severe | 1.3 ± 0.3 | 1.8 ± 0.5 | 0.5 ± 0.0 |
Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature \>=37.5 degree C and categorized as \>=37.5 to 38.4 degree C,\>38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).
| Percentage of participants | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Fever: >=37.5 degree C | 20.2 ± 15.1 | 21.2 ± 16.0 | 18.1 ± 13.2 |
| Fever: >=37.5 to 38.4 degree C | 15.2 ± 10.8 | 17.6 ± 12.8 | 14.9 ± 10.4 |
| Fever: >38.4 to 38.9 degree C | 3.1 ± 1.3 | 2.3 ± 0.7 | 1.9 ± 0.5 |
| Fever: >38.9 to 40.0 degree C | 1.8 ± 0.5 | 1.4 ± 0.3 | 1.4 ± 0.3 |
| Fever: >40.0 degree C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Decreased appetite: Mild | 4.5 ± 2.2 | 6.8 ± 3.8 | 5.1 ± 2.6 |
| Decreased appetite: Moderate | 5.8 ± 3.1 | 5.0 ± 2.5 | 4.7 ± 2.3 |
| Decreased appetite: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Drowsiness: Mild | 39.9 ± 33.4 | 48.6 ± 41.9 | 39.5 ± 33.0 |
| Drowsiness: Moderate | 3.1 ± 1.3 | 4.1 ± 1.9 | 2.3 ± 0.8 |
| Drowsiness: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Irritability: Mild | 12.6 ± 8.5 | 16.7 ± 12.0 | 10.2 ± 6.5 |
| Irritability: Moderate | 12.1 ± 8.1 | 14.9 ± 10.5 | 15.3 ± 10.8 |
| Irritability: Severe | 1.3 ± 0.3 | 0.5 ± 0.0 | 1.4 ± 0.3 |
Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature \>=37.5 degree C and categorized as \>=37.5 to 38.4 degree C,\>38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).
| Percentage of participants | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Fever: >=37.5 degree C | 15.3 ± 10.8 | 19.9 ± 14.9 | 15.3 ± 10.8 |
| Fever: >=37.5 to 38.4 degree C | 13.5 ± 9.3 | 16.3 ± 11.7 | 12.6 ± 8.4 |
| Fever: >38.4 to 38.9 degree C | 1.4 ± 0.3 | 2.7 ± 1.0 | 1.9 ± 0.5 |
| Fever: >38.9 to 40.0 degree C | 0.5 ± 0.0 | 0.9 ± 0.1 | 0.9 ± 0.1 |
| Fever: >40.0 degree C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Decreased appetite: Mild | 5.0 ± 2.5 | 7.2 ± 4.2 | 4.2 ± 1.9 |
| Decreased appetite: Moderate | 2.7 ± 1.0 | 3.6 ± 1.6 | 3.7 ± 1.6 |
| Decreased appetite: Severe | 0.5 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Drowsiness: Mild | 24.8 ± 19.2 | 32.6 ± 26.4 | 32.6 ± 26.3 |
| Drowsiness: Moderate | 1.4 ± 0.3 | 1.8 ± 0.5 | 1.4 ± 0.3 |
| Drowsiness: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Irritability: Mild | 16.7 ± 12.0 | 10.9 ± 7.1 | 14.0 ± 9.6 |
| Irritability: Moderate | 8.6 ± 5.2 | 9.0 ± 5.6 | 13.0 ± 8.8 |
| Irritability: Severe | 0.5 ± 0.0 | 0 ± 0.0 | 0.9 ± 0.1 |
Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature \>=37.5 degree C and categorized as \>=37.5 to 38.4 degree C,\>38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).
| Percentage of participants | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Fever: >=37.5 degree C | 42.7 ± 36.0 | 39.5 ± 33.0 | 38.2 ± 31.6 |
| Fever: >=37.5 to 38.4 degree C | 25.7 ± 20.0 | 29.1 ± 23.2 | 24.1 ± 18.5 |
| Fever: >38.4 to 38.9 degree C | 10.1 ± 6.4 | 5.9 ± 3.2 | 6.1 ± 3.3 |
| Fever: >38.9 to 40.0 degree C | 6.4 ± 3.6 | 4.5 ± 2.2 | 8.0 ± 4.7 |
| Fever: >40.0 degree C | 0.5 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Decreased appetite: Mild | 6.4 ± 3.6 | 6.8 ± 3.9 | 6.1 ± 3.3 |
| Decreased appetite: Moderate | 7.3 ± 4.3 | 7.7 ± 4.6 | 5.7 ± 3.0 |
| Decreased appetite: Severe | 0 ± 0.0 | 0 ± 0.0 | 0.9 ± 0.1 |
| Drowsiness: Mild | 24.3 ± 18.8 | 23.6 ± 18.2 | 29.7 ± 23.7 |
| Drowsiness: Moderate | 1.4 ± 0.3 | 2.3 ± 0.7 | 1.9 ± 0.5 |
| Drowsiness: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Irritability: Mild | 14.2 ± 9.9 | 15.5 ± 10.9 | 15.1 ± 10.6 |
| Irritability: Moderate | 7.3 ± 4.3 | 11.4 ± 7.5 | 9.4 ± 5.9 |
| Irritability: Severe | 0.9 ± 0.1 | 0.9 ± 0.1 | 0.5 ± 0.0 |
An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
| Percentage of participants | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3 | 47.6 ± 40.9 | 55.4 ± 48.6 | 58.5 ± 51.7 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
| Percentage of participants | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Percentage of Participants With AEs From Dose 4 to 1 Month After Dose 4 | 40.4 ± 33.8 | 43.2 ± 36.5 | 43.9 ± 37.1 |
A serious AE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; congenital anomaly/birth defect and other important medical events.
| Percentage of participants | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 4 | 6.2 ± 3.4 | 4.0 ± 1.9 | 7.4 ± 4.3 |
An NDCMC was defined as a significant disease or medical condition, not previously identified, that is expected to be persistent or was otherwise long-lasting in its effects.
| Percentage of participants | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 1 Month After Dose 4 | 10.7 ± 7.0 | 8.9 ± 5.5 | 8.3 ± 5.0 |
Pneumococcal serotype-specific IgG Concentrations were measured for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. The predefined levels, \>=0.35 micrograms/mL for all serotypes except for serotypes 5 (\>=0.23 micrograms/mL), 6B (\>=0.10 micrograms/mL) and 19A (\>=0.12 micrograms/mL).
| Percentage of participants | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Serotype: 1 | 97.7 (94.8 to 99.3) | 99.1 (96.8 to 99.9) | 92.0 (87.5 to 95.3) |
| Serotype: 3 | 96.4 (93.0 to 98.4) | 99.1 (96.8 to 99.9) | 95.3 (91.5 to 97.7) |
| Serotype: 4 | 96.8 (93.6 to 98.7) | 99.1 (96.8 to 99.9) | 94.8 (90.9 to 97.4) |
| Serotype: 5 | 92.3 (88.0 to 95.5) | 97.3 (94.2 to 99.0) | 93.0 (88.7 to 96.0) |
| Serotype: 6A | 90.0 (85.3 to 93.7) | 98.2 (95.4 to 99.5) | 94.8 (90.9 to 97.4) |
| Serotype: 6B | 87.8 (82.7 to 91.8) | 96.4 (93.0 to 98.4) | 82.2 (76.3 to 87.1) |
| Serotype: 7F | 95.9 (92.4 to 98.1) | 99.1 (96.8 to 99.9) | 94.8 (90.9 to 97.4) |
| Serotype: 9V | 95.9 (92.4 to 98.1) | 98.6 (96.1 to 99.7) | 93.0 (88.7 to 96.0) |
| Serotype: 14 | 96.8 (93.6 to 98.7) | 97.7 (94.8 to 99.3) | 96.2 (92.7 to 98.4) |
| Serotype: 18C | 96.8 (93.6 to 98.7) | 99.1 (96.8 to 99.9) | 94.8 (90.9 to 97.4) |
| Serotype: 19A | 99.5 (97.5 to 100.0) | 99.5 (97.5 to 100.0) | 99.1 (96.6 to 99.9) |
| Serotype: 19F | 100.0 (98.3 to 100.0) | 100.0 (98.3 to 100.0) | 100.0 (98.3 to 100.0) |
| Serotype: 23F | 89.6 (84.8 to 93.3) | 93.6 (89.6 to 96.5) | 88.7 (83.7 to 92.6) |
| Serotype: 8 | 99.5 (97.5 to 100.0) | 0.9 (0.1 to 3.3) | 99.5 (97.4 to 100.0) |
| Serotype: 10A | 60.2 (53.4 to 66.7) | 1.8 (0.5 to 4.6) | 59.6 (52.7 to 66.3) |
| Serotype: 11A | 100.0 (98.3 to 100.0) | 2.7 (1.0 to 5.8) | 100.0 (98.3 to 100.0) |
| Serotype: 12F | 74.7 (68.4 to 80.3) | 0.9 (0.1 to 3.2) | 74.6 (68.3 to 80.3) |
| Serotype: 15B | 99.1 (96.8 to 99.9) | 8.2 (4.9 to 12.6) | 98.6 (95.9 to 99.7) |
| Serotype: 22F | 100.0 (98.3 to 100.0) | 0.9 (0.1 to 3.2) | 100.0 (98.3 to 100.0) |
| Serotype: 33F | 95.0 (91.2 to 97.5) | 3.2 (1.3 to 6.4) | 92.5 (88.0 to 95.6) |
Pneumococcal serotype-specific IgG concentrations were measured for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Assay results below the LLOQ were set to 0.5\*LLOQ.
| Micrograms per milliliter | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Serotype 1 | 1.37 (1.25 to 1.51) | 2.21 (1.98 to 2.47) | 1.17 (1.04 to 1.31) |
| Serotype 3 | 1.29 (1.18 to 1.41) | 1.81 (1.66 to 1.98) | 1.10 (0.99 to 1.22) |
| Serotype 4 | 1.76 (1.57 to 1.97) | 2.96 (2.64 to 3.32) | 1.73 (1.52 to 1.97) |
| Serotype 5 | 1.01 (0.89 to 1.16) | 1.72 (1.51 to 1.96) | 1.00 (0.87 to 1.14) |
| Serotype 6A | 1.38 (1.21 to 1.57) | 2.34 (2.09 to 2.62) | 1.64 (1.42 to 1.88) |
| Serotype 6B | 0.42 (0.35 to 0.50) | 0.83 (0.71 to 0.97) | 0.39 (0.32 to 0.48) |
| Serotype 7F | 1.58 (1.43 to 1.75) | 2.19 (1.95 to 2.46) | 1.52 (1.35 to 1.71) |
| Serotype 9V | 1.46 (1.32 to 1.61) | 2.11 (1.88 to 2.36) | 1.45 (1.29 to 1.64) |
| Serotype 14 | 2.79 (2.45 to 3.18) | 3.31 (2.90 to 3.78) | 2.43 (2.13 to 2.76) |
| Serotype 18C | 1.67 (1.51 to 1.86) | 2.52 (2.26 to 2.82) | 1.54 (1.38 to 1.72) |
| Serotype 19A | 2.41 (2.19 to 2.65) | 3.19 (2.86 to 3.56) | 2.36 (2.11 to 2.64) |
| Serotype 19F | 2.81 (2.60 to 3.04) | 3.73 (3.41 to 4.08) | 2.76 (2.53 to 3.02) |
| Serotype 23F | 1.32 (1.15 to 1.51) | 2.05 (1.79 to 2.34) | 1.29 (1.13 to 1.48) |
| Serotype 8 | 3.32 (3.05 to 3.61) | 0.01 (0.01 to 0.01) | 3.29 (2.97 to 3.64) |
| Serotype 10A | 0.50 (0.42 to 0.60) | 0.01 (0.01 to 0.02) | 0.47 (0.39 to 0.56) |
| Serotype 11A | 5.63 (5.17 to 6.14) | 0.02 (0.02 to 0.02) | 5.22 (4.73 to 5.77) |
| Serotype 12F | 0.79 (0.67 to 0.93) | 0.01 (0.01 to 0.01) | 0.72 (0.60 to 0.85) |
| Serotype 15B | 6.77 (6.04 to 7.60) | 0.04 (0.03 to 0.05) | 6.80 (6.03 to 7.67) |
| Serotype 22F | 4.94 (4.54 to 5.38) | 0.01 (0.00 to 0.01) | 4.41 (3.99 to 4.88) |
| Serotype 33F | 1.70 (1.51 to 1.92) | 0.02 (0.02 to 0.03) | 1.62 (1.40 to 1.87) |
Pneumococcal serotype-specific IgG concentrations were measured for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F.
| Micrograms per milliliter | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Serotype 1 | 2.79 (2.50 to 3.12) | 4.62 (4.11 to 5.19) | 2.78 (2.47 to 3.12) |
| Serotype 3 | 0.97 (0.87 to 1.08) | 1.44 (1.30 to 1.59) | 1.08 (0.96 to 1.21) |
| Serotype 4 | 6.93 (6.14 to 7.83) | 10.01 (8.89 to 11.27) | 7.31 (6.51 to 8.20) |
| Serotype 5 | 2.96 (2.63 to 3.34) | 4.64 (4.13 to 5.21) | 2.94 (2.59 to 3.33) |
| Serotype 6A | 11.90 (10.61 to 13.34) | 17.25 (15.66 to 18.99) | 13.92 (12.43 to 15.59) |
| Serotype 6B | 7.18 (6.30 to 8.18) | 10.48 (9.46 to 11.61) | 7.50 (6.58 to 8.55) |
| Serotype 7F | 4.46 (4.04 to 4.92) | 6.62 (5.95 to 7.38) | 4.85 (4.34 to 5.42) |
| Serotype 9V | 4.54 (4.04 to 5.09) | 6.62 (5.93 to 7.39) | 5.38 (4.81 to 6.02) |
| Serotype 14 | 8.23 (7.27 to 9.31) | 10.30 (9.25 to 11.47) | 9.19 (8.10 to 10.43) |
| Serotype 18C | 3.95 (3.50 to 4.45) | 5.97 (5.27 to 6.75) | 3.81 (3.38 to 4.30) |
| Serotype 19A | 7.62 (6.82 to 8.52) | 8.97 (8.08 to 9.95) | 7.92 (7.06 to 8.89) |
| Serotype 19F | 8.74 (7.84 to 9.73) | 11.02 (9.96 to 12.20) | 8.56 (7.66 to 9.56) |
| Serotype 23F | 7.01 (6.16 to 7.97) | 11.76 (10.42 to 13.28) | 7.39 (6.49 to 8.42) |
| Serotype 8 | 5.84 (5.23 to 6.53) | 0.02 (0.02 to 0.03) | 5.88 (5.23 to 6.62) |
| Serotype 10A | 6.98 (6.13 to 7.93) | 0.01 (0.01 to 0.01) | 8.02 (7.02 to 9.16) |
| Serotype 11A | 5.73 (5.08 to 6.46) | 0.02 (0.01 to 0.02) | 5.78 (5.14 to 6.50) |
| Serotype 12F | 2.73 (2.41 to 3.09) | 0.01 (0.01 to 0.01) | 2.69 (2.36 to 3.06) |
| Serotype 15B | 18.45 (16.73 to 20.36) | 0.03 (0.03 to 0.04) | 21.83 (19.53 to 24.41) |
| Serotype 22F | 14.07 (12.67 to 15.63) | 0.00 (0.00 to 0.01) | 14.21 (12.61 to 16.00) |
| Serotype 33F | 10.29 (9.28 to 11.40) | 0.02 (0.01 to 0.02) | 11.13 (9.99 to 12.39) |
20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. OPA titers were determined in randomly selected subsets of sera from each vaccine group.
| Titers | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Serotype 1:1 Month after Dose 3 | 55 (43 to 71) | 126 (104 to 152) | 56 (45 to 70) |
| Serotype 1:Before Dose. 4 | 11 (10 to 12) | 13 (11 to 16) | 10 (9 to 11) |
| Serotype 1:1 Month after Dose 4 | 162 (125 to 210) | 386 (306 to 486) | 194 (150 to 251) |
| Serotype 3:1 Month after Dose 3 | 107 (86 to 134) | 170 (147 to 196) | 120 (103 to 139) |
| Serotype 3:Before Dose 4 | 16 (13 to 20) | 20 (16 to 25) | 16 (12 to 20) |
| Serotype 3: 1 Month after Dose 4 | 131 (114 to 150) | 193 (165 to 226) | 150 (126 to 179) |
| Serotype 4:1 Month after Dose 3 | 1864 (1565 to 2219) | 1768 (1393 to 2245) | 1617 (1298 to 2015) |
| Serotype 4: Before Dose 4 | 25 (18 to 37) | 44 (29 to 66) | 21 (15 to 28) |
| Serotype 4:1 Month after Dose 4 | 1627 (1232 to 2148) | 2038 (1471 to 2825) | 1544 (1224 to 1948) |
| Serotype 5:1 Month after Dose 3 | 95 (79 to 114) | 154 (131 to 183) | 91 (77 to 109) |
| Serotype 5:Before Dose 4 | 16 (15 to 17) | 18 (16 to 19) | 15 (14 to 16) |
| Serotype 5:1 Month after Dose 4 | 172 (140 to 212) | 248 (204 to 303) | 141 (112 to 179) |
| Serotype 6A:1 Month after Dose 3 | 2709 (2283 to 3213) | 3339 (2777 to 4013) | 3120 (2562 to 3799) |
| Serotype 6A:Before Dose 4 | 83 (56 to 122) | 173 (116 to 258) | 95 (62 to 147) |
| Serotype 6A:1 Month after Dose 4 | 3249 (2686 to 3928) | 5455 (4379 to 6795) | 3489 (2831 to 4300) |
| Serotype 6B:1 Month after Dose 3 | 1548 (1247 to 1921) | 2489 (2005 to 3088) | 1563 (1215 to 2010) |
| Serotype 6B:Before Dose 4 | 40 (29 to 54) | 75 (49 to 115) | 44 (31 to 63) |
| Serotype 6B:1 Month after Dose 4 | 2304 (1811 to 2933) | 4319 (3478 to 5362) | 2552 (2006 to 3247) |
| Serotype 7F:1 Month after Dose 3 | 4160 (3406 to 5081) | 4428 (3821 to 5131) | 4491 (3675 to 5490) |
| Serotype 7F:Before Dose 4 | 626 (436 to 899) | 761 (579 to 1000) | 689 (487 to 975) |
| Serotype 7F:1 Month after Dose 4 | 4735 (3824 to 5863) | 6361 (5024 to 8054) | 4703 (3704 to 5972) |
| Serotype 9V:1 Month after Dose 3 | 1807 (1432 to 2279) | 2388 (1986 to 2870) | 1929 (1554 to 2394) |
| Serotype 9V:Before Dose 4 | 183 (134 to 251) | 204 (151 to 274) | 212 (149 to 302) |
| Serotype 9V:1 Month after Dose 4 | 4199 (3322 to 5309) | 5162 (4349 to 6127) | 4201 (3418 to 5164) |
| Serotype 14:1 Month after Dose 3 | 1922 (1429 to 2585) | 2593 (1999 to 3362) | 2103 (1527 to 2897) |
| Serotype 14:Before Dose 4 | 426 (307 to 592) | 469 (346 to 634) | 357 (251 to 509) |
| Serotype 14:1 Month after Dose 4 | 1673 (1331 to 2102) | 1706 (1385 to 2102) | 2005 (1631 to 2463) |
| Serotype 18C:1 Month after Dose 3 | 5124 (4381 to 5992) | 5355 (4617 to 6212) | 4908 (4037 to 5967) |
| Serotype 18C:Before Dose 4 | 122 (76 to 198) | 173 (112 to 267) | 89 (56 to 143) |
| Serotype 18C:1 Month after Dose 4 | 4477 (3528 to 5681) | 6315 (5081 to 7848) | 4249 (3355 to 5381) |
| Serotype 19A:1 Month after Dose 3 | 638 (535 to 762) | 676 (551 to 830) | 553 (441 to 693) |
| Serotype 19A:Before Dose 4 | 13 (10 to 18) | 20 (14 to 28) | 12 (10 to 16) |
| Serotype 19A:1 Month after Dose 4 | 1860 (1530 to 2261) | 2534 (2044 to 3143) | 1722 (1379 to 2151) |
| Serotype 19F:1 Month after Dose 3 | 449 (356 to 566) | 624 (494 to 788) | 488 (411 to 580) |
| Serotype 19F:Before Dose 4 | 26 (24 to 29) | 25 (24 to 26) | 26 (23 to 29) |
| Serotype 19F:1 Month after Dose 4 | 1071 (846 to 1356) | 1783 (1364 to 2331) | 962 (753 to 1230) |
| Serotype 23F:1 Month after Dose 3 | 1580 (1211 to 2061) | 1849 (1499 to 2281) | 1402 (1103 to 1782) |
| Serotype 23F:Before Dose 4 | 42 (24 to 73) | 62 (36 to 107) | 24 (15 to 39) |
| Serotype 23F:1 Month after Dose 4 | 2609 (2015 to 3377) | 3772 (2966 to 4796) | 2052 (1668 to 2523) |
| Serotype 8:1 Month after Dose 3 | 1532 (1215 to 1933) | 16 (15 to 18) | 1541 (1220 to 1946) |
| Serotype 8:Before Dose 4 | 166 (119 to 230) | 20 (17 to 24) | 147 (105 to 205) |
| Serotype 8:1 Month after Dose 4 | 2970 (2412 to 3658) | 27 (20 to 36) | 3208 (2525 to 4077) |
| Serotype 10A:1 Month after Dose 3 | 6977 (5204 to 9354) | 40 (33 to 47) | 6780 (5436 to 8456) |
| Serotype 10A:Before Dose 4 | 1985 (1422 to 2772) | 78 (51 to 118) | 2066 (1439 to 2967) |
| Serotype 10A:1 Month after Dose 4 | 9030 (6855 to 11893) | 87 (56 to 136) | 8269 (6252 to 10937) |
| Serotype 11A:1 Month after Dose 3 | 1894 (1540 to 2330) | 58 (47 to 71) | 1838 (1451 to 2327) |
| Serotype 11A:Before Dose 4 | 416 (258 to 670) | 95 (64 to 142) | 247 (150 to 405) |
| Serotype 11A: 1 Month after Dose 4 | 3958 (2973 to 5269) | 90 (62 to 132) | 4200 (3187 to 5534) |
| Serotype 12F:1 Month after Dose 3 | 35278 (23575 to 52790) | 24 (24 to 25) | 21475 (14378 to 32074) |
| Serotype 12F:Before Dose 4 | 3984 (3017 to 5261) | 35 (26 to 47) | 4904 (3909 to 6153) |
| Serotype 12F:1 Month after Dose 4 | 15611 (11336 to 21499) | 43 (31 to 60) | 18899 (14215 to 25125) |
| Serotype 15B:1 Month after Dose 3 | 6981 (5726 to 8511) | 17 (15 to 20) | 5707 (4129 to 7889) |
| Serotype 15B:Before Dose 4 | 578 (345 to 969) | 26 (18 to 39) | 609 (331 to 1121) |
| Serotype 15B:1 Month after Dose 4 | 7280 (5594 to 9475) | 32 (20 to 50) | 7770 (6448 to 9363) |
| Serotype 22F:1 Month after Dose 3 | 21864 (16413 to 29125) | 10 (8 to 11) | 19276 (14969 to 24822) |
| Serotype 22F:Before Dose 4 | 2562 (1869 to 3512) | 16 (11 to 24) | 2014 (1477 to 2745) |
| Serotype 22F:1 Month after Dose 4 | 28435 (19414 to 41649) | 18 (12 to 27) | 23480 (17229 to 31998) |
| Serotype 33F:1 Month after Dose 3 | 20162 (13581 to 29930) | 177 (160 to 195) | 15931 (11550 to 21974) |
| Serotype 33F:Before Dose 4 | 5678 (4403 to 7321) | 539 (391 to 742) | 6835 (5080 to 9198) |
| Serotype 33F:1 Month after Dose 4 | 18997 (13140 to 27463) | 658 (480 to 904) | 26963 (18722 to 38830) |
Pneumococcal serotype-specific IgG concentrations were measured for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. The predefined levels, \>=0.35 micrograms/mL for all serotypes except for serotypes 5 (\>=0.23 micrograms/mL), 6B (\>=0.10 micrograms/mL) and 19A (\>=0.12 micrograms/mL).
| Percentage of participants | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Serotype 1 | 99.1 | 100.0 | 98.6 |
| Serotype 3 | 91.7 | 98.6 | 91.5 |
| Serotype 4 | 100.0 | 100.0 | 100.0 |
| Serotype 5 | 99.5 | 100.0 | 99.5 |
| Serotype 6A | 100.0 | 100.0 | 100.0 |
| Serotype 6B | 100.0 | 100.0 | 100.0 |
| Serotype 7F | 99.5 | 100.0 | 100.0 |
| Serotype 9V | 99.5 | 100.0 | 100.0 |
| Serotype 14 | 99.1 | 99.5 | 100.0 |
| Serotype 18C | 99.5 | 100.0 | 100.0 |
| Serotype 19A | 100.0 | 100.0 | 100.0 |
| Serotype 19F | 100.0 | 100.0 | 100.0 |
| Serotype 23F | 99.5 | 100.0 | 99.5 |
| Serotype 8 | 100.0 | 3.2 | 100.0 |
| Serotype 10A | 99.1 | 0.9 | 99.5 |
| Serotype 11A | 100.0 | 5.9 | 100.0 |
| Serotype 12F | 98.2 | 0.0 | 98.6 |
| Serotype 15B | 100.0 | 8.6 | 100.0 |
| Serotype 22F | 100.0 | 1.8 | 100.0 |
| Serotype 33F | 100.0 | 2.7 | 100.0 |
GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. The GMFR from 1 month after Dose 3 to before Dose 4 was reported from participants in Dose 3 evaluable immunogenicity population.
| Fold rise | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Serotype 1 | 0.2 (0.2 to 0.2) | 0.2 (0.2 to 0.2) | 0.2 (0.2 to 0.2) |
| Serotype 3 | 0.1 (0.1 to 0.1) | 0.1 (0.1 to 0.1) | 0.1 (0.1 to 0.1) |
| Serotype 4 | 0.3 (0.2 to 0.3) | 0.2 (0.2 to 0.3) | 0.3 (0.2 to 0.3) |
| Serotype 5 | 0.3 (0.2 to 0.3) | 0.2 (0.2 to 0.3) | 0.2 (0.2 to 0.3) |
| Serotype 6A | 0.5 (0.4 to 0.6) | 0.4 (0.4 to 0.4) | 0.4 (0.3 to 0.4) |
| Serotype 6B | 0.8 (0.6 to 0.9) | 0.5 (0.4 to 0.6) | 0.7 (0.6 to 0.8) |
| Serotype 7F | 0.5 (0.4 to 0.5) | 0.4 (0.4 to 0.5) | 0.5 (0.4 to 0.5) |
| Serotype 9V | 0.3 (0.2 to 0.3) | 0.3 (0.2 to 0.3) | 0.3 (0.2 to 0.3) |
| Serotype 14 | 0.7 (0.6 to 0.8) | 0.7 (0.6 to 0.8) | 0.7 (0.6 to 0.8) |
| Serotype 18C | 0.2 (0.2 to 0.2) | 0.2 (0.2 to 0.2) | 0.2 (0.2 to 0.2) |
| Serotype 19A | 0.1 (0.1 to 0.1) | 0.1 (0.1 to 0.1) | 0.1 (0.1 to 0.1) |
| Serotype 19F | 0.2 (0.1 to 0.2) | 0.1 (0.1 to 0.2) | 0.2 (0.1 to 0.2) |
| Serotype 23F | 0.2 (0.2 to 0.3) | 0.3 (0.2 to 0.3) | 0.3 (0.2 to 0.3) |
| Serotype 8 | 0.2 (0.1 to 0.2) | 1.4 (1.2 to 1.6) | 0.2 (0.1 to 0.2) |
| Serotype 10A | 2.2 (1.9 to 2.6) | 0.8 (0.6 to 0.9) | 2.3 (1.9 to 2.7) |
| Serotype 11A | 0.1 (0.1 to 0.2) | 0.8 (0.6 to 0.9) | 0.1 (0.1 to 0.2) |
| Serotype 12F | 0.4 (0.3 to 0.5) | 1.0 (0.9 to 1.1) | 0.4 (0.3 to 0.4) |
| Serotype 15B | 0.4 (0.4 to 0.5) | 0.6 (0.5 to 0.7) | 0.4 (0.3 to 0.4) |
| Serotype 22F | 0.4 (0.3 to 0.4) | 0.6 (0.5 to 0.8) | 0.4 (0.3 to 0.4) |
| Serotype 33F | 1.1 (0.9 to 1.2) | 0.6 (0.5 to 0.7) | 1.0 (0.9 to 1.2) |
GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. The GMFR from 1 month after Dose 3 to 1 month after Dose 4 was reported from participants in both the Dose 3 and Dose 4 evaluable immunogenicity population.
| Fold rise | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Serotype 1 | 2.0 (1.8 to 2.2) | 2.1 (1.9 to 2.3) | 2.4 (2.2 to 2.7) |
| Serotype 3 | 0.7 (0.7 to 0.8) | 0.8 (0.7 to 0.9) | 1.0 (0.9 to 1.1) |
| Serotype 4 | 3.9 (3.4 to 4.4) | 3.4 (3.0 to 3.8) | 4.3 (3.7 to 4.8) |
| Serotype 5 | 2.9 (2.6 to 3.3) | 2.7 (2.4 to 3.0) | 3.0 (2.6 to 3.4) |
| Serotype 6A | 8.6 (7.5 to 9.8) | 7.3 (6.5 to 8.3) | 8.6 (7.6 to 9.8) |
| Serotype 6B | 17.1 (14.3 to 20.4) | 12.6 (10.8 to 14.7) | 19.5 (16.2 to 23.5) |
| Serotype 7F | 2.8 (2.6 to 3.1) | 3.0 (2.7 to 3.3) | 3.3 (2.9 to 3.6) |
| Serotype 9V | 3.1 (2.8 to 3.5) | 3.1 (2.8 to 3.5) | 3.8 (3.4 to 4.2) |
| Serotype 14 | 2.9 (2.6 to 3.4) | 3.1 (2.7 to 3.6) | 3.9 (3.3 to 4.5) |
| Serotype 18C | 2.3 (2.1 to 2.6) | 2.4 (2.1 to 2.6) | 2.5 (2.3 to 2.8) |
| Serotype 19A | 3.2 (2.8 to 3.6) | 2.8 (2.5 to 3.1) | 3.4 (3.0 to 3.8) |
| Serotype 19F | 3.1 (2.8 to 3.4) | 2.9 (2.6 to 3.3) | 3.1 (2.8 to 3.5) |
| Serotype 23F | 5.3 (4.6 to 6.1) | 5.7 (5.0 to 6.5) | 5.8 (5.1 to 6.6) |
| Serotype 8 | 1.8 (1.6 to 2.0) | 1.7 (1.5 to 2.0) | 1.8 (1.6 to 2.0) |
| Serotype 10A | 14.0 (11.8 to 16.5) | 0.8 (0.7 to 1.0) | 17.5 (14.7 to 20.7) |
| Serotype 11A | 1.0 (0.9 to 1.1) | 0.8 (0.7 to 1.0) | 1.1 (1.0 to 1.2) |
| Serotype 12F | 3.4 (3.0 to 3.9) | 1.0 (1.0 to 1.1) | 3.9 (3.4 to 4.4) |
| Serotype 15B | 2.7 (2.4 to 3.1) | 0.9 (0.7 to 1.1) | 3.3 (2.9 to 3.7) |
| Serotype 22F | 2.9 (2.6 to 3.1) | 0.7 (0.6 to 0.9) | 3.2 (2.9 to 3.6) |
| Serotype 33F | 6.0 (5.3 to 6.7) | 0.7 (0.6 to 0.9) | 7.1 (6.2 to 8.1) |
GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. The GMFR from before Dose 4 to 1 month after Dose 4 was reported from participants in the Dose 4 evaluable immunogenicity population.
| Fold rise | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Serotype 1 | 10.7 (9.6 to 11.9) | 12.1 (11.0 to 13.3) | 12.6 (11.3 to 14.0) |
| Serotype 3 | 7.5 (6.6 to 8.4) | 7.9 (7.1 to 8.8) | 8.9 (8.0 to 10.0) |
| Serotype 4 | 15.0 (13.2 to 17.1) | 14.3 (12.7 to 16.0) | 16.5 (14.8 to 18.5) |
| Serotype 5 | 10.8 (9.8 to 12.0) | 11.8 (10.7 to 13.1) | 12.2 (11.0 to 13.6) |
| Serotype 6A | 17.6 (15.7 to 19.6) | 18.4 (16.6 to 20.5) | 22.1 (19.8 to 24.7) |
| Serotype 6B | 22.3 (19.9 to 24.9) | 24.3 (21.9 to 27.0) | 26.9 (23.9 to 30.2) |
| Serotype 7F | 6.0 (5.5 to 6.6) | 7.2 (6.5 to 8.0) | 6.8 (6.2 to 7.5) |
| Serotype 9V | 11.8 (10.5 to 13.2) | 12.0 (10.8 to 13.3) | 13.9 (12.4 to 15.6) |
| Serotype 14 | 4.3 (3.8 to 4.9) | 4.4 (3.9 to 5.0) | 5.7 (5.0 to 6.6) |
| Serotype 18C | 11.7 (10.5 to 12.9) | 14.0 (12.7 to 15.4) | 12.7 (11.5 to 14.1) |
| Serotype 19A | 34.2 (30.0 to 38.9) | 37.6 (33.2 to 42.6) | 38.3 (33.4 to 44.0) |
| Serotype 19F | 18.8 (16.6 to 21.4) | 21.4 (19.0 to 24.2) | 19.9 (17.6 to 22.4) |
| Serotype 23F | 22.6 (20.1 to 25.5) | 22.6 (19.8 to 25.7) | 22.7 (20.1 to 25.7) |
| Serotype 8 | 10.8 (9.6 to 12.1) | 1.3 (1.2 to 1.4) | 11.2 (9.9 to 12.7) |
| Serotype 10A | 6.3 (5.6 to 7.1) | 1.1 (1.0 to 1.1) | 7.4 (6.6 to 8.3) |
| Serotype 11A | 7.0 (6.2 to 7.9) | 1.1 (1.0 to 1.2) | 8.1 (7.2 to 9.1) |
| Serotype 12F | 8.5 (7.6 to 9.4) | 1.0 (1.0 to 1.1) | 9.9 (8.9 to 10.9) |
| Serotype 15B | 6.8 (6.0 to 7.7) | 1.5 (1.3 to 1.6) | 8.7 (7.6 to 10.0) |
| Serotype 22F | 7.9 (7.1 to 8.8) | 1.2 (1.1 to 1.3) | 8.9 (8.1 to 9.9) |
| Serotype 33F | 5.7 (5.1 to 6.3) | 1.2 (1.1 to 1.3) | 6.9 (6.2 to 7.8) |
Collected over LR and SE [systematic assessment (SA)] within 7 days after Dose 1, 2, 3, or 4; SAEs (non-SA): from Day 1 up to 1 month after Dose 4; other AEs (non-SA): from Dose 1 up to 1 month after Dose 3 and from Dose 4 up to 1 month after Dose 4. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 20vPnC (SC) | 0/225 (0%) | 14/225 (6.2%) | 222/225 (98.7%) |
| 13vPnC (SC) | 0/224 (0%) | 9/224 (4%) | 223/224 (99.6%) |
| 20vPnC (IM) | 1/217 (0.5%) | 16/217 (7.4%) | 211/217 (97.2%) |
| Event | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Respiratory syncytial virus bronchiolitisInfections and infestations | 4/225 | 2/224 | 1/217 |
| Respiratory syncytial virus infectionInfections and infestations | 4/225 | 1/224 | 1/217 |
| PyrexiaGeneral disorders | 1/225 | 0/224 | 2/217 |
| Urinary tract infectionInfections and infestations | 0/225 | 0/224 | 2/217 |
| Febrile convulsionNervous system disorders | 2/225 | 0/224 | 0/217 |
| Cardio-respiratory arrestCardiac disorders | 0/225 | 0/224 | 1/217 |
| LaryngomalaciaCongenital, familial and genetic disorders | 0/225 | 0/224 | 1/217 |
| Food allergyImmune system disorders | 0/225 | 0/224 | 1/217 |
| Asymptomatic COVID-19Infections and infestations | 0/225 | 0/224 | 1/217 |
| Cellulitis orbitalInfections and infestations | 0/225 | 0/224 | 1/217 |
| Event | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) |
|---|---|---|---|
| Injection site erythema (REDNESS)General disorders | 217/225 | 217/224 | 130/217 |
| Injection site swelling (SWELLING)General disorders | 206/225 | 211/224 | 119/217 |
| Hypersomnia (INCREASED SLEEP)Nervous system disorders | 147/225 | 161/224 | 154/217 |
| Pyrexia (FEVER)General disorders | 136/225 | 135/224 | 110/217 |
| Irritability (IRRITABILITY)Psychiatric disorders | 110/225 | 119/224 | 107/217 |
| Injection site pain (PAIN)General disorders | 84/225 | 85/224 | 65/217 |
| NasopharyngitisInfections and infestations | 49/225 | 64/224 | 66/217 |
| Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders | 62/225 | 68/224 | 55/217 |
| EczemaSkin and subcutaneous tissue disorders | 22/225 | 19/224 | 32/217 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 18/225 | 11/224 | 15/217 |
Safety population included all the participants who received at least 1 dose of the investigational product (IP) with safety follow up after any vaccination.
| Age, Continuous(Months) | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) | Total |
|---|---|---|---|---|
| Mean | 2.4 ± 0.33 | 2.4 ± 0.40 | 2.4 ± 0.42 | 2.4 ± 0.39 |
| Sex: Female, Male(Participants) | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) | Total |
|---|---|---|---|---|
| Female | 117 | 114 | 106 | 337 |
| Male | 108 | 110 | 111 | 329 |
| Ethnicity (NIH/OMB)(Participants) | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 225 | 224 | 217 | 666 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 20vPnC (SC) | 13vPnC (SC) | 20vPnC (IM) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 225 | 224 | 217 | 666 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Sep 2020 to primary completion in Apr 2022, 18 months.
Results were first posted in Apr 2023, 1 year after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 18 months is above that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine